Arca
Skip to content
Tools
Tools

Globotriosylceramide

Small molecule in Homo sapiens that 3 drugs act on.

  • Drugs that act on it: 3
  • Approved: 3
  • In phases 1 to 3: 0
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 3

Approved3

  • Agalsidase alfa
  • Pegunigalsidase alfa
  • Agalsidase beta

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Globotriosylceramide hydrolytic enzyme.
        Agalsidase alfaApprovedLembasProtein or peptideHydrolytic enzyme14
        Pegunigalsidase alfaBoxed warningApprovedChiesi FarmaceuticiProtein or peptideHydrolytic enzyme6
        Agalsidase betaBoxed warningApprovedSanofiProtein or peptideHydrolytic enzyme4

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 16 in all, from ClinicalTrials.gov.
        A Two-part Study of Lembas Edge Evaluating Tolerability and Postprandial Glycemic ControlAgalsidase alfaNot applicableRecruitingLembasJul 17, 2026
        Natural History in Fabry Disease With IVS4+919G>A MutationsAgalsidase alfa—Active, not recruitingChinese University of Hong KongApr 1, 2026
        Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific TreatmentAgalsidase alfa—RecruitingWladimir MAUHIN, DrDec 11, 2025
        Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR StudyAgalsidase alfa—RecruitingYonsei UniversityNov 19, 2025
        A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseAgalsidase alfa—RecruitingTakedaSep 23, 2025
        Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world SettingPegunigalsidase alfa, Agalsidase alfa—RecruitingChiesi ItaliaAug 7, 2025
        Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and BreastfeedingPegunigalsidase alfa—RecruitingChiesi Farmaceutici S.p.A.Apr 23, 2025
        Efficacy and Safety of Enzyme Replacement Therapy in Patients With Fabry DiseaseAgalsidase beta, Agalsidase alfa—Enrolling by invitationNPO PetrovaxMar 17, 2025
        Study of the Prevalence of Acid Sphingomyelinase Deficiency/Niemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung DiseaseAgalsidase alfaNot applicableRecruitingWladimir MAUHIN, DrMar 11, 2025
        A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry PatientsPegunigalsidase alfa—RecruitingChiesi Farmaceutici S.p.A.Oct 29, 2024
        A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseasePegunigalsidase alfaPhase 2 / Phase 3RecruitingChiesi Farmaceutici S.p.A.Mar 25, 2024
        German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfaPegunigalsidase alfa—Active, not recruitingUniversität MünsterOct 23, 2023
        Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry DiseasePegunigalsidase alfaPhase 2 / Phase 3RecruitingChiesi Farmaceutici S.p.A.Feb 2, 2023
        Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry DiseaseAgalsidase beta—RecruitingMackay Memorial HospitalJan 26, 2023
        A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry DiseaseAgalsidase betaPhase 3Active, not recruitingSanofiMar 15, 2022
        Fabry Disease Registry & Pregnancy Sub-registryAgalsidase beta—RecruitingGenzyme, a Sanofi CompanySep 20, 2005

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2366040, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.